27-Hydroxycholesterol, The Estrogen Receptor Modulator, Alters DNA Methylation in Breast Cancer

Overview

Journal Front Endocrinol (Lausanne)

Specialty Endocrinology

Date 2022 Apr 1

PMID 35360070

Authors

Ravindran Vini

Arumugam Rajavelu

Sreeja Sreeharshan

Affiliations

Soon will be listed here.

Abstract

27-hydroxycholesterol (27-HC) is the first known endogenous selective estrogen receptor modulator (SERM), and its elevation from normal levels is closely associated with breast cancer. A plethora of evidence suggests that aberrant epigenetic signatures in breast cancer cells can result in differential responses to various chemotherapeutics and often leads to the development of resistant cancer cells. Such aberrant epigenetic changes are mostly dictated by the microenvironment. The local concentration of oxygen and metabolites in the microenvironment of breast cancer are known to influence the development of breast cancer. Hence, we hypothesized that 27-HC, an oxysterol, which has been shown to induce breast cancer progression estrogen receptor alpha (ERα) and liver X receptor (LXR) and by modulating immune cells, may also induce epigenetic changes. For deciphering the same, we treated the estrogen receptor-positive cells with 27-HC and identified DNA hypermethylation on a subset of genes by performing DNA bisulfite sequencing. The genes that showed significant DNA hypermethylation were and . Furthermore, we found that 27-HC weakens the DNMT3B association with the ERα in MCF-7 cells. This study reports that 27-HC induces aberrant DNA methylation changes on the promoters of a subset of genes through modulation of ERα and DNMT3B complexes to induce the local DNA methylation changes, which may dictate drug responses and breast cancer development.

Citing Articles

Endoscopic surgery affects the gut microbiota and its metabolism in breast cancer patients.

Li J, Gao F, Li R, Chen Z, Chen G, Fan P Front Microbiol. 2025; 15():1481582.

PMID: 39839115 PMC: 11747589. DOI: 10.3389/fmicb.2024.1481582.

Liver X Receptors (LXRs) in cancer-an Eagle's view on molecular insights and therapeutic opportunities.

Ramalingam P, Elangovan S, Mekala J, Arumugam S Front Cell Dev Biol. 2024; 12:1386102.

PMID: 38550382 PMC: 10972936. DOI: 10.3389/fcell.2024.1386102.

Modulation of neural gene networks by estradiol in old rhesus macaque females.

Cervera-Juanes R, Zimmerman K, Wilhelm L, Zhu D, Bodie J, Kohama S Geroscience. 2024; 46(6):5819-5841.

PMID: 38509416 PMC: 11493911. DOI: 10.1007/s11357-024-01133-z.

DNA Methylation-Based Diagnosis and Treatment of Breast Cancer.

Peng X, Zheng J, Liu T, Zhou Z, Song C, Zhang D Curr Cancer Drug Targets. 2024; 25(1):26-37.

PMID: 38441008 DOI: 10.2174/0115680096278978240204162353.

Larsucosterol: endogenous epigenetic regulator for treating chronic and acute liver diseases.

Wang Y, Ren J, Ren S Am J Physiol Endocrinol Metab. 2024; 326(5):E577-E587.

PMID: 38381400 PMC: 11376820. DOI: 10.1152/ajpendo.00406.2023.

References

Wu Q, Odwin-Dacosta S, Cao S, Yager J, Tang W . Estrogen down regulates COMT transcription via promoter DNA methylation in human breast cancer cells. Toxicol Appl Pharmacol. 2019; 367:12-22. DOI: 10.1016/j.taap.2019.01.016. View

Busk P . A tool for design of primers for microRNA-specific quantitative RT-qPCR. BMC Bioinformatics. 2014; 15:29. PMC: 3922658. DOI: 10.1186/1471-2105-15-29. View

Zhang Y, Rohde C, Tierling S, Stamerjohanns H, Reinhardt R, Walter J . DNA methylation analysis by bisulfite conversion, cloning, and sequencing of individual clones. Methods Mol Biol. 2008; 507:177-87. DOI: 10.1007/978-1-59745-522-0_14. View

Messeguer X, Escudero R, Farre D, Nunez O, Martinez J, Alba M . PROMO: detection of known transcription regulatory elements using species-tailored searches. Bioinformatics. 2002; 18(2):333-4. DOI: 10.1093/bioinformatics/18.2.333. View

Hurtado A, Holmes K, Ross-Innes C, Schmidt D, Carroll J . FOXA1 is a key determinant of estrogen receptor function and endocrine response. Nat Genet. 2010; 43(1):27-33. PMC: 3024537. DOI: 10.1038/ng.730. View

Nelson E, Wardell S, Jasper J, Park S, Suchindran S, Howe M . 27-Hydroxycholesterol links hypercholesterolemia and breast cancer pathophysiology. Science. 2013; 342(6162):1094-8. PMC: 3899689. DOI: 10.1126/science.1241908. View

Hegde M, Joshi M . Comprehensive analysis of regulation of DNA methyltransferase isoforms in human breast tumors. J Cancer Res Clin Oncol. 2021; 147(4):937-971. PMC: 7954751. DOI: 10.1007/s00432-021-03519-4. View

Ward E, Vareslija D, Charmsaz S, Fagan A, Browne A, Cosgrove N . Epigenome-wide SRC-1-Mediated Gene Silencing Represses Cellular Differentiation in Advanced Breast Cancer. Clin Cancer Res. 2018; 24(15):3692-3703. DOI: 10.1158/1078-0432.CCR-17-2615. View

Folger O, Jerby L, Frezza C, Gottlieb E, Ruppin E, Shlomi T . Predicting selective drug targets in cancer through metabolic networks. Mol Syst Biol. 2011; 7:501. PMC: 3159974. DOI: 10.1038/msb.2011.35. View

10.

Chang W, Fa H, Xiao D, Wang J . Targeting phosphatidylserine for Cancer therapy: prospects and challenges. Theranostics. 2020; 10(20):9214-9229. PMC: 7415799. DOI: 10.7150/thno.45125. View

11.

Stone A, Zotenko E, Locke W, Korbie D, Millar E, Pidsley R . DNA methylation of oestrogen-regulated enhancers defines endocrine sensitivity in breast cancer. Nat Commun. 2015; 6:7758. PMC: 4510968. DOI: 10.1038/ncomms8758. View

12.

Cirera S, Busk P . Quantification of miRNAs by a simple and specific qPCR method. Methods Mol Biol. 2014; 1182:73-81. DOI: 10.1007/978-1-4939-1062-5_7. View

13.

Shen Z, Jiao K, Teng M, Li Z . Activation of STAT-3 signalling by RECK downregulation ROS is involved in the 27-hydroxycholesterol-induced invasion in breast cancer cells. Free Radic Res. 2020; 54(2-3):126-136. DOI: 10.1080/10715762.2020.1715965. View

14.

Baek A, Yu Y, He S, Wardell S, Chang C, Kwon S . The cholesterol metabolite 27 hydroxycholesterol facilitates breast cancer metastasis through its actions on immune cells. Nat Commun. 2017; 8(1):864. PMC: 5636879. DOI: 10.1038/s41467-017-00910-z. View

15.

Shi S, Lee E, Lin Y, Chen L, Zheng H, He X . Recruitment of monocytes and epigenetic silencing of intratumoral CYP7B1 primarily contribute to the accumulation of 27-hydroxycholesterol in breast cancer. Am J Cancer Res. 2019; 9(10):2194-2208. PMC: 6834472. View

16.

Ou Z, Wada T, Gramignoli R, Li S, Strom S, Huang M . MicroRNA hsa-miR-613 targets the human LXRα gene and mediates a feedback loop of LXRα autoregulation. Mol Endocrinol. 2011; 25(4):584-96. PMC: 3063084. DOI: 10.1210/me.2010-0360. View

17.

Wang G, Anastassiou D . Pan-cancer driver copy number alterations identified by joint expression/CNA data analysis. Sci Rep. 2020; 10(1):17199. PMC: 7566486. DOI: 10.1038/s41598-020-74276-6. View

18.

Handy D, Castro R, Loscalzo J . Epigenetic modifications: basic mechanisms and role in cardiovascular disease. Circulation. 2011; 123(19):2145-56. PMC: 3107542. DOI: 10.1161/CIRCULATIONAHA.110.956839. View

19.

Wu Q, Ishikawa T, Sirianni R, Tang H, McDonald J, Yuhanna I . 27-Hydroxycholesterol promotes cell-autonomous, ER-positive breast cancer growth. Cell Rep. 2013; 5(3):637-45. PMC: 3950897. DOI: 10.1016/j.celrep.2013.10.006. View

20.

Mei J, Xu R, Hao L, Zhang Y . MicroRNA-613: A novel tumor suppressor in human cancers. Biomed Pharmacother. 2019; 123:109799. DOI: 10.1016/j.biopha.2019.109799. View